Toxic Substances Control Act reform: Market Trends

The Toxic Substances Control Act reform remains a central axis for U.S. chemical safety policy, technology risk management, and market strategy. Since the 2016 Lautenberg amendments, the EPA has pursued a more proactive, risk-based approach to evaluating existing chemicals and reviewing new ones. In the past year, policymakers, industry groups, and health advocates have traded rhetoric and data-driven arguments about how to balance robust public protections with practical innovation and manufacturing needs. The result is a dynamic moment for investors, product teams, and regulators: the scope and cadence of TSCA reform are evolving in real time, with concrete implications for compliance costs, supply chains, and the pace of new chemical introductions. This piece synthesizes the latest data, case studies, and market signals to explain what’s changing, why it’s happening, and how organizations should prepare for the year ahead.

In practical terms, the current frame of TSCA reform is not only about new regulatory rules; it’s about a redefined risk management philosophy, a broader set of data requirements, and a shifting balance between environmental health protections and industrial competitiveness. The administration’s policy agenda emphasizes efficiency and robust oversight, while congressional activity has featured both bipartisan reforms and industry-aligned proposals. The implications touch multiple industries—from plastics and consumer electronics to healthcare devices and manufacturing. For readers in technology and markets, the key question is how risk evaluation timelines, data reporting demands, and new-use constraints will influence product design, supply chain resilience, and the economics of bringing advanced materials to market. (epa.gov)

What's Happening

Congressional TSCA reform push

Legislative activity around Toxic Substances Control Act reform has intensified in 2025 and 2026, with lawmakers proposing a range of changes—from targeted PFAS regulation to broader improvements in risk evaluation and cost recovery. In early 2026, a draft bill from the House aimed at expanding EPA oversight and potentially constraining or restructuring certain review processes drew intense industry and public health scrutiny. News coverage and policy trackers highlight the tension between accelerating safety reviews and shielding industry from perceived regulatory overreach. At the same time, related bills, such as H.R.6626 addressing PFAS exposure and remedies, have moved through committee consideration, signaling the ongoing legislative interest in reforming how the federal framework handles toxic substances. (congress.gov)

Case study reference: In early 2026, a prominent draft bill from the House Energy and Commerce Committee surfaced with provisions that would recalibrate EPA review timelines and adjust how PFAS are treated within the framework, underscoring the adversarial yet bipartisan nature of reform debates. While industry groups argue for predictability and cost containment, public health advocates warn that weakening protections could raise exposure risks. The policy debate is playing out against a backdrop of current agency actions and court challenges related to data reporting and risk evaluation. (toxicfreefuture.org)

Risk evaluations cadence and data flows

The U.S. Environmental Protection Agency has continued to refine its risk evaluation cadence under TSCA, with proposals to improve efficiency, assign risk determinations for each condition of use, and streamline the review process for chemicals already in commerce. In September 2025, the EPA released a proposal to revise the risk-evaluation framework, aiming to make assessments more predictable, scientifically robust, and aligned with Congressional intent. This aligns with ongoing agency work to modernize how risks are quantified, communicated, and acted upon, including efforts to expand health and safety data requirements for existing chemicals and to tighten the review of new chemicals, particularly PFAS and other persistent, bioaccumulative, and toxic substances. (epa.gov)

• The EPA’s 2024-2025 work on PFAS risk evaluation and broader framework updates shows a deliberate push to ensure high-priority chemistries undergo full, robust safety review, rather than streamlined or loophole-based assessments. A notable element is the December 2024 rule changes that eliminate low-volume exemptions for PFAS and similar substances, guaranteeing comprehensive pre-market review. This signals a long-term shift toward more conservative, precautionary risk management for chemicals with high exposure potential. (epa.gov)

• The agency’s ongoing activities in the New Chemicals Program reflect a broad data strategy shift: finalizing significant new use rules, requiring SNURs for certain uses, and continuing to publish monthly statistics on submissions, exemptions, and risk assessments. These data streams underpin policy choices and industry expectations about how quickly new products can move to market under TSCA reform. (epa.gov)

Case studies and real-world examples

Case study A: Phthalates risk evaluations. In 2024-2025, the EPA issued schedules for risk evaluations of five phthalates (BBP, DBP, DEHP, DIBP, DCHP) and planned additional analyses to support cross-chemical assessments. The agency set a timetable for final risk evaluations (DIDP and DINP) and cross-phthalates risk analyses, illustrating how TSCA reform translates into concrete agency actions with timed milestones that affect manufacturers and downstream users. This scheduling illustrates how data-driven evaluation work influences product formulations, supplier choices, and regulatory planning. (epa.gov)

Case study B: Data reporting and compliance timelines. In December 2024, EPA finalized a health and safety data reporting rule for 16 chemicals being considered for risk evaluation, with a May 22, 2026 reporting deadline (later extended in 2025). This data collection effort is a keystone for informed risk management, anonymized by the confidentiality rules but essential for designing safer products and more accurate risk models. The delay and extension have already influenced industry readiness and internal data governance investments. (epa.gov)

Table 1 (brief comparison): Current vs proposed risk-evaluation framework under TSCA reform

• Current framework (as of 2024–2025): Comprehensive risk evaluations for high-priority existing chemicals; risk management actions required when risks are identified; PFAS pre-market review tightened; new-chemical reviews subject to SNURs and data submissions.
• Proposed/adjusted framework (2025–2026): Aims to make risk determinations for each condition of use; increase efficiency and consistency in evaluations; tighten or adjust data requirements for new chemicals and phthalates; enhance transparency and stakeholder input while maintaining scientific rigor. Sources: EPA rule updates and proposed framework changes; 2024–2025 PFAS actions. (epa.gov)

Why It’s Happening

Market forces and competitive pressure

The push for TSCA reform reflects a convergence of market pressures: supply-chain resilience, the cost of compliance, and the need to bring safer products faster to market. With global competition and evolving consumer expectations, firms in plastics, electronics, and advanced materials face a complex regulatory landscape that rewards transparent data, safer chemistries, and robust lifecycle thinking. Agencies are recalibrating risk-evaluation methods to reduce regulatory uncertainty while preserving health protections, which in turn shapes investment decisions and R&D prioritization. The 2024 TSCA fees rule and the 2025 framework proposals underscore efforts to secure sustainable funding for ongoing chemical safety reviews, enabling more reliable planning for product development and compliance budgets. (epa.gov)

Tech and social drivers

Advances in data science, toxicology, and alternative materials science are accelerating the ability to substitute hazardous chemicals with safer options. PFAS, a persistent focus of TSCA reform, exemplifies the tension between performance needs and safety requirements: EPA’s PFAS-related framework updates stress full safety reviews and elimination of exemptions for certain PFAS, pushing industry to invest in safer formulations and alternative chemistries. These tech shifts directly influence product design cycles, supplier ecosystems, and the pace at which new products can be developed and scaled. (epa.gov)

Policy and enforcement signals

The Lautenberg amendments remain the backbone of the modern TSCA, establishing the mandatory evaluation of chemicals, a framework for risk-based assessments, and more funding transparency. As agencies implement these provisions, Congress has shown continued interest in refining the law, with bills that would expand oversight or, conversely, propose carve-outs or expedited paths for certain chemicals. The existence of these bills—along with agency rulemaking and court decisions around data reporting—creates a policy environment that is both stable in its core protections and dynamic in its regulatory tactics. (epa.gov)

What It Means

Business impact and cost considerations

TSCA reform affects the cost structure of chemical safety reviews, testing, and compliance. The 2018 TSCA Fees Rule, amended in 2024, requires that the EPA recovers 25% of authorized costs for chemical-safety reviews, providing a more sustainable funding model but also raising the cost of regulatory compliance for manufacturers. The adjustment in fees, effective for the agency’s review activities, has direct implications for budgeting, pricing, and supply-chain planning for firms across sectors. For some companies, the changes reinforce the value of safer, preferrable chemistries as a long-term cost control strategy; for others, they raise the economics of keeping hazardous substances in use. (epa.gov)

Consumer and market effects

From a consumer perspective, TSCA reform translates into more robust chemical safety assurances, particularly for products containing PFAS or other high-profile substances. The policy emphasis on full safety reviews before market entry and the strengthening of data reporting can improve public confidence in product safety, while potentially extending development timelines for certain chemicals and materials. The market thus sees a twofold effect: a push toward safer formulations and a need to maintain product timelines amid more stringent data and testing requirements. (epa.gov)

Industry changes and compliance environments

Industries most directly affected include those relying on high-volume chemical inputs and complex supply chains—plastics, textiles, electronics, and consumer goods. The reform trajectory suggests a continued emphasis on quantitative risk assessments, rigorous data transparency, and pre-market evaluation for many high-risk chemicals. Firms are likely to see increased demand for robust supplier data, better exposure analytics, and proactive substitution planning, alongside new opportunities in safer chemistries and green materials. The ongoing risk-evaluation cadence and SNURs for new chemicals feed directly into product lifecycle mapping and procurement strategies. (epa.gov)

Looking Ahead

6–12 month predictions

• Risk-evaluation reform will continue to accelerate with proposals to assign risk determinations to conditions of use, potentially shortening or clarifying decision timelines for chemicals already in commerce. Expect regulatory agencies to publish further proposed amendments to the 2024 Risk Evaluation Framework Rule and to issue additional cross-chemical analyses as part of phthalate and PFAS programs. (epa.gov)
• PFAS-specific governance will sharpen, with continued emphasis on pre-market review and more rigorous testing data requirements, likely influencing market strategies for products that rely on PFAS-related performance characteristics. Firms may prioritize safer alternatives and innovative shielding technologies to comply with tighter rules. (epa.gov)
• Legislative dynamics will persist, with committees considering bills that both strengthen protections and propose regulatory reforms. The mix of bipartisan and industry-influenced proposals will create a spectrum of potential futures for TSCA implementation, and market participants should monitor committee actions and floor votes for early signals. (congress.gov)

Opportunities for business and policy preparedness

• Invest in data governance and toxicology capabilities. The health-and-safety data reporting rules for 16 chemicals (with a May 2026 deadline) demonstrate the strategic value of upstream data collection, which informs risk evaluations and helps companies demonstrate safer product use profiles. Implementing robust data pipelines and standardized exposure assessments can shorten internal timelines and improve negotiation power with suppliers. (epa.gov)
• Prioritize safer chemistries and substitutes. As PFAS and other high-risk substances come under heightened scrutiny, companies should map their chemical inventories to identify opportunities for substitution with safer alternatives while maintaining performance. The agency’s phthalates risk-evaluation schedule highlights how cross-chemical analyses and cumulative risk assessments shape product design choices. (epa.gov)
• Build adaptive compliance programs. The continuation of risk-evaluation cadence and SNUR updates requires agile compliance teams that can respond to new rules, data requests, and potential exemptions. The EPA’s ongoing updates to the New Chemicals Regulations show a trend toward more explicit expectations for regulated actors, with an emphasis on preventing unsafe introductions. (epa.gov)

Comparison table: TSCA reform milestones and anticipated timelines

• Lautenberg Act (2016) established the modern framework: mandatory evaluations, risk-based assessments, and funding transparency. This is the foundational reform that continues to guide subsequent rulemaking and court challenges. (epa.gov)
• 2018 TSCA Fees Rule and 2024 amendments: financial sustainability and efficiency of chemical reviews, with a target of recovering 25% of authorized costs. This affects budgeting and project planning for manufacturers and regulators alike. (epa.gov)
• 2024 Framework Rule and 2025–2026 proposed changes: proposals to assign risk determinations by condition of use, expanded PFAS reviews, and efficiency improvements. These shape near-term product development, testing strategies, and regulatory interactions. (epa.gov)
• 2025–2026 legislative activity: ongoing bills in Congress reflecting divergent views on how TSCA should function in a modern economy, including PFAS accountability and broader oversight shifts. (congress.gov)

Quotes from the field

“This work is yet another example of how we can and will protect human health and the environment while allowing manufacturing and industrial sectors to thrive.” — EPA Administrator on risk-evaluation efficiency proposals. (Quoted in EPA’s 2025 risk-evaluation reform release.) (epa.gov)

Case studies and practical implications

• Phthalates risk-evaluation schedule (DIDP, DINP, and cross-chemical analyses) demonstrates how TSCA reform translates into publicly visible milestone timelines that affect industry planning, supplier contracts, and product formulation cycles. The schedule indicates that final risk evaluations for certain phthalates were anticipated by late 2025, with a broader cross-chemical framework to follow, illustrating both the long horizon and the specificity of regulatory action under reform. (epa.gov)
• PFAS data reporting and review processes show how data collection rules drive compliance investments and risk-management strategies. The March–May 2026 deadline extension creates a window for companies to optimize data capture and align internal databases with EPA expectations, while still keeping the overall reform trajectory intact. (epa.gov)

Expanded section: how the numbers inform the story

• New chemical reviews and PMN submissions have shown substantial activity since 2016, with thousands of submissions and hundreds of exemptions granted or denied annually. As of 2025, the EPA reported thousands of PMN submissions historically, and the agency continues to publish monthly statistics that reveal ongoing intensity in the program. This data-driven dynamic indicates a market where compliance costs and data requirements are a routine part of the product-development cycle for many firms. (epa.gov)
• The ongoing risk-evaluation cadence includes both completed and in-progress evaluations of numerous chemicals, including asbestos and other substances with well-documented exposure concerns. The public-facing lists provide transparency into which chemicals are prioritized, the current status, and the expected near-term regulatory actions. This transparency is critical for corporate risk management and investor decision-making as firms navigate regulatory uncertainty and data demands. (epa.gov)

Closing thoughts Toxic Substances Control Act reform continues to shape the intersection of technology, markets, and health policy. The data-driven push to strengthen risk-based evaluations and expand robust data reporting creates a more transparent and precautionary framework for chemical safety, while legislative activity signals a likelihood of further adjustments in the years ahead. For technology companies and market participants, the prudent path is to view TSCA reform not as a compliance burden alone but as a signal to invest in safer chemistries, smarter data architecture, and resilient supply chains that can weather regulatory swings. The next 6–12 months will be telling: watch for more explicit condition-of-use risk determinations, PFAS-focused actions, and the continued evolution of funding mechanisms that sustain the responsible governance of chemicals in commerce. (epa.gov)